SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001549595-24-000073
Filing Date
2024-05-21
Accepted
2024-05-21 07:06:54
Documents
13
Period of Report
2024-05-20
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K nrix-20240520.htm   iXBRL 8-K 42418
  Complete submission text file 0001549595-24-000073.txt   170084

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nrix-20240520.xsd EX-101.SCH 1901
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT nrix-20240520_lab.xml EX-101.LAB 22548
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nrix-20240520_pre.xml EX-101.PRE 13046
16 EXTRACTED XBRL INSTANCE DOCUMENT nrix-20240520_htm.xml XML 2824
Mailing Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 (415) 660-5320
Nurix Therapeutics, Inc. (Filer) CIK: 0001549595 (see all company filings)

IRS No.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
Type: 8-K | Act: 34 | File No.: 001-39398 | Film No.: 24966821
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)